NR3C2 and COVID-19: Sites of potential pharmacological actions of MR activation in COVID-19 include reduction in polarization towards the M1 proinflammatory phenotype (M1Mφ) in macrophages, reduction in proinflammatory Th17 CD4+ lymphocytes and reduction in cytotoxic IFNγ+-CD8+ T lymphocytes [7].